Targeted Approaches toward Understanding and Treating Pulmonary Lymphangioleiomyomatosis (LAM)

Hormones and Cancer

Volumn 4, Issue 2, 2013, Pages 70-77

  Hammes, Stephen R ^a   Krymskaya, Vera P ^b  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPACTIN; MAMMALIAN TARGET OF RAPAMYCIN; MEVINOLIN; PRAVASTATIN; RAPAMYCIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); SIMVASTATIN;

CANCER GROWTH; DEATH; DISEASE COURSE; DISEASE EXACERBATION; GENE FUNCTION; GENE INACTIVATION; GENE MUTATION; HAMARTOMA; HUMAN; INTRACELLULAR SIGNALING; LUNG CYST; LUNG FUNCTION; LUNG TRANSPLANTATION; LYMPHANGIOLEIOMYOMATOSIS; NONHUMAN; PATHOPHYSIOLOGY; PREGNANCY; PRIORITY JOURNAL; PULMONARY LYMPHANGIOLEIOMYOMATOSIS; RARE DISEASE; REVIEW; SPONTANEOUS PNEUMOTHORAX; TUBEROUS SCLEROSIS;

EID: 84874405761     PISSN: 18688497     EISSN: 18688500     Source Type: Journal    
DOI: 10.1007/s12672-012-0128-4     Document Type: Review

References (85)

1. Astrinidis A, Khare L, Carsillo T, Smolarek T, Au KS, Northrup H, Henske EP (2000) Mutational analysis of the tuberous sclerosis gene TSC2 in patients with pulmonary lymphangioleiomyomatosis. J Med Genet 37(1): 55-57.
2. Awonuga AO, Shavell VI, Imudia AN, Rotas M, Diamond MP, Puscheck EE (2010) Pathogenesis of benign metastasizing leiomyoma: a review. Obstet Gynecol Surv 65(3): 189-195. doi: 10. 1097/OGX. 0b013e3181d60f93.
3. Bissler JJ, McCormack FX, Young LR, Elwing JM, Chuck G, Leonard JM, Schmithorst VJ et al (2008) Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 358(2): 140-151. doi: 10. 1056/NEJMoa063564.
4. Bowen JM, Cates JM, Kash S, Itani D, Gonzalez A, Huang D, Oliveira A, Bridge JA (2012) Genomic imbalances in benign metastasizing leiomyoma: characterization by conventional karyotypic, fluorescence in situ hybridization, and whole genome SNP array analysis. Cancer Genet 205(5): 249-254. doi: 10. 1016/j. cancergen. 2012. 04. 005.
5. Brunelli A, Catalini G, Fianchini A (1996) Pregnancy exacerbating unsuspected mediastinal lymphangioleiomyomatosis and chylothorax. Int J Gynaecol Obstet 52(3): 289-290.
6. Cai X, Pacheco-Rodriguez G, Fan Q-Y, Haughey M, Samsel L, El-Chemaly S, Wu HP et al (2010) Phenotypic characterization of disseminated cells with TSC2 loss of heterozygosity in patients with lymphangioleiomyomatosis. Am J Resp Crit Care Med 182(11): 1410-1418.
7. Cai S-L, Tee AR, Short JD, Bergeron JM, Kim J, Shen J, Guo R, Johnson CL, Kiguchi K, Walker CL (2006) Activity of TSC2 is inhibited by AKT-mediated phosphorylation and membrane partitioning. J Cell Biol 173(2): 279-289.
8. Carsillo T, Astrinidis A, Henske EP (2000) Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. Proc Natl Acad Sci U S A 97(11): 6085-6090.
9. Darling TN, Pacheco-Rodriguez G, Gorio A, Lesma E, Walker C, Moss J (2010) Lymphangioleiomyomatosis and TSC2-/- cells. Lymph Res Biol 8(1): 59-69. doi: 10. 1089/lrb. 2009. 0031.
10. Davies DM, de Vries PJ, Johnson SR, McCartney DL, Cox JA, Serra AL, Watson PC et al (2011) Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial. Clin Cancer Res 17(12): 4071-4081. doi: 10. 1158/1078-0432. ccr-11-0445.
11. Demierre M-F, Peter DR, Higgins SB, Gruber EH, Lippman SM (2005) Statins and cancer prevention. Nat Rev Cancer 5(12): 930-942.
12. Dilling DF, Gilbert ER, Picken MM, Eby J, Love RB, Le Poole IC (2012) A current viewpoint of lymphangioleiomyomatosis supporting immunotherapeutic treatment options. Am J Respir Cell Mol Biol 46: 1-5.
13. Egan DF, Shackelford DB, Mihaylova MM, Gelino S, Kohnz RA, Mair W, Vasquez DS et al (2011) Phosphorylation of ULK1 (hATG1) by AMP-activated protein kinase connects energy sensing to mitophagy. Science 331(6016): 456-461. doi: 10. 1126/science. 1196371.
14. El-Chemaly S, Taveira-DaSilva A, Stylianou MP, Moss J (2009) Statins in lymphangioleiomyomatosis: a word of caution. Eur Respir J 34(2): 513-514. doi: 10. 1183/09031936. 00012709.
15. El-Hashemite N, Kwiatkowski DJ (2005) Interferon-γ-Jak-Stat signaling in pulmonary lymphangioleiomyomatosis and renal angiomyolipoma: a potential therapeutic target. Am J Respir Cell Mol Biol 33(3): 227-230.
16. El-Hashemite N, Walker V, Kwiatkowski DJ (2005) Estrogen enhances whereas tamoxifen retards development of Tsc mouse liver hemangioma: a tumor related to renal angiomyolipoma and pulmonary lymphangioleiomyomatosis. Cancer Res 65(6): 2474-2481. doi: 10. 1158/0008-5472. CAN-04-3840.
17. El-Hashemite N, Zhang H, Walker V, Hoffmeister KM, Kwiatkowski DJ (2004) Perturbed IFN-γ-Jak-signal transducers and activators of transcription signaling in tuberous sclerosis mouse models: synergistic effects of rapamycin-IFN-γ treatment. Cancer Res 64(10): 3436-3443.
18. Etienne-Manneville S, Hall A (2002) Rho GTPases in cell biology. Nature 420(6916): 629-635.
19. Fielhaber JA, Han Y-S, Tan J, Xing S, Biggs CM, Joung K-B, Kristof AS (2009) Inactivation of mammalian target of rapamycin increases STAT1 nuclear content and transcriptional activity in {alpha}4- and protein phosphatase 2A-dependent fashion. J Biol Chem 284(36): 24341-24353. doi: 10. 1074/jbc. M109. 033530.
20. Finlay GA, Malhowski AJ, Liu Y, Fanburg BL, Kwiatkowski DJ, Toksoz D (2007) Selective inhibition of growth of tuberous sclerosis complex 2 Null cells by atorvastatin is associated with impaired Rheb and Rho GTPase function and reduced mTOR/S6 kinase activity. Cancer Res 67(20): 9878-9886. doi: 10. 1158/0008-5472. can-07-1394.
21. Fiore MG, Sanguedolce F, Lolli I, Piscitelli D, Ricco R (2005) Abdominal lymphangioleiomyomatosis in a man with Klinefelter syndrome: the first reported case. Ann Diagn Pathol 9(2): 96-100, S1092913404001650.
22. Franz DN, Leonard J, Tudor C, Chuck G, Care M, Sethuraman G, Dinopoulos A, Thomas G, Crone KR (2006) Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol 59(3): 490-498.
23. Glasgow CG, Steagall WK, Taveira-Dasilva A, Pacheco-Rodriguez G, Cai X, El-Chemaly S, Moses M, Darling T, Moss J (2010) Lymphangioleiomyomatosis (LAM): molecular insights lead to targeted therapies. Respir Med 104(Suppl 1): S45-S58, S0954-6111(10)00135-6.
24. Glasgow CG, Steagall WK, Taveira-DaSilva A, Pacheco-Rodriguez G, Xiong C, El-Chemaly S, Moses M, Thomas D, Moss J (2010) Lymphangioleiomyomatosis (LAM): molecular insights lead to targeted therapies. Respir Med 104(Supplement 1): S45-S58.
25. Glasgow CG, Taveira-DaSilva A, Pacheco-Rodriguez G, Steagall WK, Tsukada K, Cai X, El-Chemaly S, Mos J (2009) Involvement of lymphatics in lymphangioleiomyomatosis. Lymph Res Biol 7(4): 221-228. doi: 10. 1089/lrb. 2009. 0017.
26. Goncharova EA, Goncharov DA, Chisolm A, Spaits MS, Lim PN, Cesarone G, Khavin I et al (2008) Interferon β augments tuberous sclerosis complex 2 (TSC2)-dependent inhibition of TSC2-null ELT3 and human lymphangioleiomyomatosis-derived cell proliferation. Mol Pharmacol 73(3): 778-788. doi: 10. 1124/mol. 107. 040824.
27. Goncharova EA, Goncharov DA, Damera G, Tliba O, Amrani Y, Panettieri RA, Krymskaya VP (2009) Signal transducer and activator of transcription 3 is required for abnormal proliferation and survival of TSC2-deficient cells: relevance to pulmonary lymphangioleiomyomatosis. Mol Pharmacol 76(4): 766-777.
28. Goncharova EA, Goncharov DA, Eszterhas A, Hunter DS, Glassberg MK, Yeung RS, Walker CL et al (2002) Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation: a role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis. J Biol Chem 277: 30958-30967.
29. Goncharova EA, Goncharov DA, Fehrenbach M, Khavin I, Duka B, Hino O, Colby TV et al (2012) Prevention of alveolar destruction and airspace enlargement in a mouse model of pulmonary lymphangioleiomyomatosis (LAM). Sci Transl Med 4(154): 154ra134.
30. Goncharova EA, Goncharov DA, Li H, Pimtong W, Stephen L, Khavin I, Krymskaya VP (2011) mTORC2 is required for proliferation and survival of TSC2-null cells. Mol Cell Biol 31(12): 2484-2498. doi: 10. 1128/mcb. 01061-10.
31. Goncharova EA, Goncharov DA, Lim PN, Noonan D, Krymskaya VP (2006) Modulation of cell migration and invasiveness by tumor suppressor TSC2 in Lymphangioleiomyomatosis. Am J Respir Cell Mol Biol 34: 473-480.
32. Goncharova E, Goncharov D, Noonan D, Krymskaya VP (2004) TSC2 modulates actin cytoskeleton and focal adhesion through TSC1-binding domain and the Rac1 GTPase. J Cell Biol 167(6): 1171-1182.
33. Goncharova EA, Goncharov DA, Spaits M, Noonan D, Talovskaya E, Eszterhas A, Krymskaya VP (2006) Abnormal smooth muscle cell growth in LAM: role for tumor suppressor TSC2. Am J Respir Cell Mol Biol 34: 561-572.
34. Goncharova EA, Krymskaya VP (2008) Pulmonary lymphangioleiomyomatosis (LAM): progress and current challenges. J Cell Biochem 103: 369-382.
35. Goyle KK, Moore DF Jr, Garrett C, Goyle V (2003) Benign metastasizing leiomyomatosis: case report and review. Am J Clin Oncol 26(5): 473-476. doi: 10. 1097/01. coc. 0000037737. 78080.
36. Hammes SR, Levin ER (2011) Minireview: recent advances in extranuclear steroid receptor actions. Endocrinology 152(12): 4489-4495. doi: 10. 1210/en. 2011-1470.
37. Hayashi T, Kumasaka T, Mitani K, Terao Y, Watanabe M, Oide T, Nakatani Y et al (2011) Prevalence of uterine and adnexal involvement in pulmonary lymphangioleiomyomatosis: a clinicopathologic study of 10 patients. Am J Surg Pathol 35(12): 1776-1785. doi: 10. 1097/PAS. 0b013e318235edbd.
38. Herry I, Neukirch C, Debray M-P, Mignon F, Crestani B (2007) Dramatic effect of sirolimus on renal angiomyolipomas in a patient with tuberous sclerosis complex. Eur J Intern Med 18(1): 76-77. doi: 10. 1016/j. ejim. 2006. 07. 017.
39. Hino O, Kobayashi T, Mitani H (2002) Prevention of hereditary carcinogenesis. Proc Jpn Acad 78: 30-32.
40. Hohman DW, Noghrehkar D, Ratnayake S (2008) Lymphangioleiomyomatosis: a review. Eur J Intern Med 19(5): 319-324. doi: 10. 1016/j. ejim. 2007. 10. 015.
41. Inoki K, Guan K-L (2009) Tuberous sclerosis complex, implication from a rare genetic disease to common cancer treatment. Hum Mol Genet 18(R1): R94-R100. doi: 10. 1093/hmg/ddp032.
42. Inoki K, Li Y, Tian X, Guan K-L (2003) Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev 17(15): 1829-1834.
43. Inoki K, Ouyang H, Zhu T, Lindvall C, Wang Y, Zhang X, Yang Q, Bennett C, Harada Y, Stankunas K (2006) TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell 126(5): 955-968.
44. Inoki K, Zhu T, Guan KL (2003) TSC2 mediates cellular energy response to control cell growth and survival. Cell 115: 577-590.
45. Jacinto E, Loewith R, Schmidt A, Lin S, Ruegg MA, Hall A, Hall MN (2004) Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 6(11): 1122-1128.
46. Johnson SR (2006) Lymphangioleiomyomatosis. Eur Respir J 27(5): 1056-1065. doi: 10. 1183/09031936. 06. 00113303.
47. Johnson SR, Tattersfield AE (1999) Decline in lung function in lymphangioleiomyomatosis: relation to menopause and progesterone treatment. Am J Respir Crit Care Med 160(2): 628-633.
48. Juvet SC, McCormack FX, Kwiatkowski DJ, Downey GP (2006) Molecular pathogenesis of lymphangioleiomyomatosis: lessons learned from orphans. Am J Respir Cell Mol Biol 36: 398-408.
49. Karbowniczek M, Astrinidis A, Balsara BR, Testa JR, Lium JH, Colby TV, McCormack FX, Henske EP (2003) Recurrent lymphangiomyomatosis after transplantation: genetic analyses reveal a metastatic mechanism. Am J Respir Crit Care Med 167(7): 976-982. doi: 10. 1164/rccm. 200208-969OC.
50. Kim J, Kundu M, Viollet B, Guan K-L (2011) AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat Cell Biol 13(2): 132-141.
51. Kristof AS, You Z, Han Y-S, Giaid A (2010) Protein expression of urotensin II, urotensin-related peptide and their receptor in the lungs of patients with lymphangioleiomyomatosis. Peptides 31(8): 1511-1516. doi: 10. 1016/j. peptides. 2010. 04. 017.
52. Krymskaya VP (2008) Smooth muscle-like cells in lymphangioleiomyomatosis. Proc Am Thorac Soc 5: 119-126.
53. Krymskaya VP (2012) Treatment option(s) for pulmonary lymphangioleiomyomatosis: progress and current challenges. Am J Respir Cell Mol Biol 46(5): 563-565.
54. Lamb RF, Roy C, Diefenbach TJ, Vinters HV, Johnson MW, Jay DG, Hall A (2000) The TSC1 tumour suppressor hamartin regulates cell adhesion through ERM proteins and the GTPase Rho. Nat Cell Biology 2(5): 281-287.
55. Lee D-F, Kuo H-P, Chen C-T, Hsu J-M, Chou C-K, Wei Y, Sun H-L et al (2007) IKKβ suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. Cell 130(3): 440-455.
56. Lee N, Woodrum C, Nobil A, Rauktys A, Messina M, Dabora S (2009) Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models. BMC Pharmacol 9(1): 8.
57. Ma L, Chen Z, Erdjument-Bromage H, Tempst P, Pandolfi PP (2005) Phosphorylation and functional inactivation of TSC2 by Erk: implications for tuberous sclerosis and cancer pathogenesis. Cell 121(2): 179-193.
58. McCormack FX (2008) Lymphangioleiomyomatosis. Chest 133(2): 507-516. doi: 10. 1378/chest. 07-0898.
59. McCormack FX, Inoue Y, Moss J, Singer LG, Strange C, Nakata K, Barker AF et al (2011) Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med 364: 1595-1606. doi: 10. 1056/NEJMoa1100391.
60. Meraj R, Wikenheiser-Brokamp KA, Young LR, McCormack FX (2012) Lymphangioleiomyomatosis: new concepts in pathogenesis, diagnosis, and treatment. Semin Respir Crit Care Med 33(05): 486-497. doi: 10. 1055/s-0032-1325159.
61. Ohori NP, Yousem SA, Sonmez-Alpan E, Colby TV (1991) Estrogen and progesterone receptors in lymphangioleiomyomatosis, epithelioid hemangioendothelioma, and sclerosing hemangioma of the lung. Am J Clin Pathol 96(4): 529-535.
62. Parkhitko A, Myachina F, Morrison TA, Hindi KM, Auricchio N, Karbowniczek M, Wu JJ et al (2011) Tumorigenesis in tuberous sclerosis complex is autophagy and p62/sequestosome 1 (SQSTM1)-dependent. Proc Natl Acad Sci 108(30): 12455-12460. doi: 10. 1073/pnas. 1104361108.
63. Sahai E, Marshal CJ (2002) Rho-GTPases and cancer. Nat Rev Cancer 2: 133-142.
64. Sarbassov DD, Ali Siraj M, Do-Hyung K, Guertin DA, Latek RR, Erdjument-Bromage H, Tempst P, Sabatini DM (2004) Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 14(14): 1296-1302.
65. Sato T, Seyama K, Fujii H, Maruyama H, Setoguchi Y, Iwakami S, Fukuchi Y, Hino O (2002) Mutation analysis of the TSC1 and TSC2 genes in Japanese patients with pulmonary lymphangioleiomyomatosis. J Hum Genet 47(1): 20-28. doi: 10. 1007/s10038-002-8651-8.
66. Schiavina M, Di Scioscio V, Contini P, Cavazza A, Fabiani A, Barberis M, Bini A et al (2007) Pulmonary lymphangioleiomyomatosis in a karyotypically normal man without tuberous sclerosis complex. Am J Respir Crit Care Med 176(1): 96-98. doi: 10. 1164/rccm. 200610-1408CR.
67. Schmelzle T, Hall MN (2000) TOR, a central controller of cell growth. Cell 103: 253-262.
68. Schmidt A, Bickle M, Beck T, Hall MN (1997) The yeast phosphatidylinositol kinase homolog TOR2 activates RHO1 and RHO2 via the exchange factor ROM2. Cell 88: 531-542.
69. Seyama K, Kumasaka T, Kurihara M, Mitani K, Sato T (2010) Lymphangioleiomyomatosis: a disease involving the lymphatic system. Lymphat Res Biol 8(1): 21-31. doi: 10. 1089/lrb. 2009. 0018.
70. Shen A, Iseman MD, Waldron JA, King TE (1987) Exacerbation of pulmonary lymphangioleiomyomatosis by exogenous estrogens. Chest 91(5): 782-785.
71. Smolarek TA, Wessner LL, McCormack FX, Mylet JC, Menon AG, Henske EP (1998) Evidence that lymphangiomyomatosis is caused by TSC2 mutations: chromosome 16p13 loss of heterozygosity in angiomyolipomas and lymph nodes from women with lymphangiomyomatosis. Am J Hum Genet 62(4): 810-815. doi: 10. 1086/301804.
72. Smolarek TA, Wessner LL, McCormack FX, Mylet JC, Menon AG, Henske EP (1998) Evidence that lymphangiomyomatosis is caused by TSC2 mutations: chromosome 16p13 loss of heterozygosity in angiolipomas and lymph nodes from women with lymphangiomyomatosis. Am J Hum Genet 62: 810-815.
73. Taveira-DaSilva AM, Pacheco-Rodriguez G, Moss J (2010) The natural history of lymphangioleiomyomatosis: markers of severity, rate of progression and prognosis. Lymph Res Biol 8(1): 9-19. doi: 10. 1089/lrb. 2009. 0024.
74. Taveira-DaSilva AM, Stylianou MP, Hedin CJ, Hathaway O, Moss J (2004) Decline in lung function in patients with lymphangioleiomyomatosis treated with or without progesterone. Chest 126(6): 1867-1874. doi: 10. 1378/chest. 126. 6. 1867.
75. Tee AR, Manning BD, Roux PP, Cantley LC, Blenis J (2003) Tuberous sclerosis complex gene products, tuberin and hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr Biol 13(15): 1259-1268.
76. Tietze L, Gunther K, Horbe A, Pawlik C, Klosterhalfen B, Handt S, Merkelbach-Bruse S (2000) Benign metastasizing leiomyoma: a cytogenetically balanced but clonal disease. Hum Pathol 31(1): 126-128.
77. Travis WD, Colby TV, Koss MN, Rosado-de-Christenson ML, Müller NL, King TE Jr (2002) AFIP atlas of nontumor pathology: non-neoplastic disorders of the lower respiratory tract. American Registry of Pathology, Washington, DC.
78. Wahedna I, Cooper S, Williams J, Paterson IC, Britton JR, Tattersfield AE (1994) Relation of pulmonary lymphangio-leiomyomatosis to use of the oral contraceptive pill and fertility in the UK: a national case control study. Thorax 49(9): 910-914.
79. Walker CL, Hunter D, Everitt JI (2003) Uterine leiomyoma in the Eker rat: a unique model for important diseases of women. Genes Chromosome Cancer 38(4): 349-356. doi: 10. 1002/gcc. 10281.
80. Young LR, VanDyke R, Gulleman PM, Inoue Y, Brown KK, Schmidt LS, Linehan WM et al (2010) Serum vascular endothelial growth factor-D prospectively distinguishes lymphangioleiomyomatosis from other diseases. Chest 138(3): 674-681. doi: 10. 1378/chest. 10-0573.
81. Yu J, Astrinidis A, Howard S, Henske EP (2004) Estradiol and tamoxifen stimulate LAM-associated angiomyolipoma cell growth and activate both genomic and nongenomic signaling pathways. Am J Physiol Lung Cell Mol Physiol 286(4): L694-L700. doi: 10. 1152/ajplung.
82. Yu J, Henske EP (2010) mTOR activation, lymphangiogenesis, and estrogen-mediated cell survival: the "perfect storm" of pro-metastatic factors in LAM pathogenesis. Lymphat Res Biol 8(1): 43-49. doi: 10. 1089/lrb. 2009. 0020.
83. Yu JJ, Robb VA, Morrison TA, Ariazi EA, Karbowniczek M, Astrinidis A, Wang C et al (2009) Estrogen promotes the survival and pulmonary metastasis of tuberin-null cells. Proc Natl Acad Sci U S A 106(8): 2635-2640. doi: 10. 1073/pnas. 0810790106.
84. Yu JJ, Robb VA, Morrison TA, Ariazi EA, Karbowniczek M, Astrinidis A, Wang C et al (2009) Estrogen promotes the survival and pulmonary metastasis of tuberin-null cells. Proc Natl Acad Sci 106(8): 2635-2640. doi: 10. 1073/pnas. 0810790106.
85. Zhe X, Schuger L (2004) Combined smooth muscle and melanocytic differentiation in lymphangioleiomyomatosis. J Histochem Cytochem 52(12): 1537-1542.